News
EUnetHTA 21
On 17 September 2021, the European Health and Digital Executive Agency (HaDEA) signed the Service Contract for the Provision of Joint Health Technology Assessment (HTA) Work
Future Model of Cooperation (FMC) – White Paper
EUnetHTA has become synonymous with HTA in Europe, a trademark, in fact, that stands for a community of professionals dedicated to continuously improve the standards
OTCA26 Obesity Surgery Project – Final Assessment now available
The final report is now available for the Relative Effectiveness Assessment OTCA26 “Surgical procedures for treatment of obesity”. The aim of this multi-technology HTA was
EUnetHTA Magazine Summer 2021 – now available
We are pleased to publish the EUnetHTA Magazine for Summer 2021, the last issue of Joint Action 3 (2016-2021). While the magazine is intended to
PTJA16 – Venetoclax in combination with an hypomethylating agent for treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy – final assessment now available
This is the pharmaceutical Joint Assessment PTJA16 – Venetoclax with a hypomethylating agent fort he treatment of adult patients with newly diagnosed acute myeloid leukaemia
EUnetHTA and EMA take stock of their cooperation
The European Network for Health Technology Assessment (EUnetHTA) and the European Medicines Agency (EMA) have published a Technical Report on their achievements since 2017.
EUnetHTA-EMA April Meeting – minutes now available
We are pleased to publish the minutes for the EUnetHTA-EMA Bilateral meeting held online on 28 April, 2021. This meeting concluded the EMA/EUnetHTA work plan
PTRCR20 – Bamlanivimab for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.
This is the fourth pharmaceutical Rapid Collaborative Review (PTRCR20) published by EUnetHTA. In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed
PTJA17 – Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD) – project plan now available
The final project plan of the relative effectiveness assessment of ‘Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD)’ is now available for access. The
Engaging Stakeholder in Joint Action 3 – now available for access
As Joint Action 3 (JA3) comes to a close, an overview of stakeholder interaction has been prepared that focusses on who our stakeholders are, the
